COMPASS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
COMPASS THERAPEUTICS, INC. (CMPX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 9.68 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 370.00K shares.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 9.31M shares, a 107.74% increase year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 185.00K shares, a 57.95% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 110.00K shares, a 95.22% decline year-over-year.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.78M shares, a 22.86% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.19M shares, a 120.94% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.80M shares, a 23.10% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.28M shares, a 24.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 370.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 9.68M shares 10-Q · filed 2026-08-06 | 9.87M shares derived: sum of 3 quarters · filed 2026-08-06 | 9.98M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 9.31M shares 10-Q · filed 2026-05-05 | 9.50M shares derived: sum of 2 quarters · filed 2026-05-05 | 9.61M shares derived: sum of 3 quarters · filed 2026-05-05 | 9.61M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 185.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 295.00K shares derived: sum of 2 quarters · filed 2026-03-05 | 295.00K shares derived: sum of 3 quarters · filed 2026-03-05 | 4.78M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 110.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 110.00K shares derived: sum of 2 quarters · filed 2025-11-05 | 4.59M shares 10-Q · filed 2025-11-05 | 5.03M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 4.48M shares 10-Q · filed 2025-08-11 | 4.92M shares derived: sum of 3 quarters · filed 2026-03-05 | 7.22M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | 4.48M shares 10-Q · filed 2025-05-08 | 4.92M shares derived: sum of 2 quarters · filed 2026-03-05 | 7.22M shares derived: sum of 3 quarters · filed 2026-03-05 | 7.24M shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | 440.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 2.74M shares derived: sum of 2 quarters · filed 2026-03-05 | 2.75M shares derived: sum of 3 quarters · filed 2026-03-05 | 6.19M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 2.30M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 2.31M shares derived: sum of 2 quarters · filed 2024-11-12 | 5.75M shares 10-Q · filed 2024-11-12 | 5.87M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 13.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 3.45M shares 10-Q · filed 2024-08-12 | 3.57M shares derived: sum of 3 quarters · filed 2025-02-27 | 3.64M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 3.44M shares 10-Q · filed 2024-05-13 | 3.56M shares derived: sum of 2 quarters · filed 2025-02-27 | 3.63M shares derived: sum of 3 quarters · filed 2025-02-27 | 4.00M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 115.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 190.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 565.00K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.80M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 450.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 2.69M shares 10-Q · filed 2023-11-09 | 2.69M shares derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | 375.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.61M shares 10-Q · filed 2023-08-03 | 2.61M shares derived: sum of 3 quarters · filed 2024-03-21 | 4.89M shares derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | 2.24M shares 10-Q · filed 2023-05-04 | 2.24M shares derived: sum of 2 quarters · filed 2024-03-21 | 4.51M shares derived: sum of 3 quarters · filed 2024-03-21 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 2.27M shares derived: sum of 2 quarters · filed 2024-03-21 | 2.28M shares 10-K · filed 2024-03-21 | |
| 2022-09-30 | 2.27M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 2.28M shares 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | 2.23K shares 10-Q · filed 2022-08-01 | |||
| 2021-12-31 | 1.82M shares 10-K · filed 2023-03-15 | |||
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |